IP Library Granted Patent US 9,920,117
Granted Patent B2
US 9,920,117 · App. 14/786,436 · Granted Mar 20, 2018

Functional monoclonal antibody against heparin-binding epidermal growth factor-like growth factor

Inventors: Kenichiro Ono (Nagoya, JP); Junichi Akatsuka (Ina, JP)
Assignee: MEDICAL & BIOLOGICAL LABORATIVES CO., LTD.
C07K16/22C07K2317/24C07K2317/34C07K2317/732C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,920,117
App. No.
14/786,436
Granted
Mar 20, 2018
Kind
B2
Abstract

Two types of antibodies (35-1 antibody and 292 antibody) capable of binding to phenylalanine at position 115, isoleucine at position 117, glycine at position 140, glutamic acid at position 141, and arginine at position 142 of a human HB-EGF protein were successfully obtained. Then, it was also found that these antibodies had an activity of suppressing cleavage of the human HB-EGF protein, and an activity of suppressing EGFR phosphorylation that would occur when the human HB-EGF bound to the EGFR. Further, determined were amino acid sequences of light chain and heavy chain variable regions of these antibodies and sequences of CDRs of each of the variable regions.

Claims (7)

1. An antibody capable of binding to human HB-EGF, wherein the antibody is an antibody which comprises a light chain variable region containing the amino acid sequences of SEQ ID NOs: 2 to 4, and wherein the antibody further comprises a heavy chain variable region containing the amino acid sequences of SEQ ID NOs: 6 to 8.

2. A composition comprising the antibody according to claim 1 , and further comprising a pharmaceutically acceptable carrier or medium.

3. An antibody capable of binding to human HB-EGF, wherein the antibody is an antibody comprising a light chain variable region which comprises the amino acid sequence of SEQ ID NO: 5, or which comprises the amino acid sequence of SEQ ID NO: 5 but in which one to ten amino acids in the framework region are substituted, and

wherein the antibody further comprises a heavy chain variable region which comprises the amino acid sequence of SEQ ID NO: 9, or which comprises the amino acid sequence of SEQ ID NO: 9 but in which one to ten amino acids in the framework region are substituted.

4. An antibody capable of binding to human HB-EGF, wherein the antibody comprises:

a light chain variable region which comprises the amino acid sequence of SEQ ID NO: 18, or which comprises the amino acid sequence of SEQ ID NO: 18 but in which one to ten amino acids in the framework region are substituted; and

a heavy chain variable region which comprises the amino acid sequence of SEQ ID NO: 19, or which comprises the amino acid sequence of SEQ ID NO: 19 but in which one to ten amino acids in the framework region are substituted.

Assignments (2)
CHANGE OF ADDRESS Recorded Oct 28, 2022
From: MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.
To: MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.
Reel/Frame 061794/0822 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2015
From: ONO, KENICHIRO; AKATSUKA, JUNICHI
To: MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.
Reel/Frame 037266/0852 →
Priority Claims (1)
WO PCT/JP2013/061943 · Apr 23, 2013 · international
Continuity (1)
Related Publication 20160083464A1 · Mar 24, 2016